Comparative genomic hybridization (CGH) was developed to identify pathogenic DNA copy-number changes (e.g., duplications, deletions) on a genome-wide scale, and to map these changes to genomic ...
Defining regions of genomic imbalance can identify genes involved in tumour development. Conventional cytogenetics has identified several nonrandom copy number alterations (CNA) in uveal melanomas ...
PALO ALTO, Calif., Jan. 5, 2005 -- Agilent Technologies Inc. (NYSE: A) today announced a breakthrough development that enables the rapid advance of microarray-based comparative genomic studies in ...
Vemurafenib (V) in BRAF V600E metastatic melanoma (mM): Analysis of 507 patients (pts) enrolled in the French temporary authorization for use (ATU). This is an ASCO Meeting Abstract from the 2012 ASCO ...
No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2004 ASCO Annual Meeting. This abstract does not include a full text component.
Genetic aberrations that cause a gain or loss of chromosomal material are associated with mental retardation and congenital malformations and linked to development of cancer. Comparative genomic ...
Scott W. Stuart, MD, MS; Casey H. King, BA; G. Shashidar Pai, MD Such observations emphasize the importance of clarifying the origin of a genetic variation by studying the parents for comparison. The ...
Agilent Technologies Inc. and Cogenics, a division of Clinical Data, Inc. have announced that Cogenics has been recertified, for the third year, as a Certified Microarray Service Provider for Agilent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results